TCGA-HN-A2OB-01A-21R-A27Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 63
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- WNT_BETA_CATENIN_SIGNALING+0.530
- HEDGEHOG_SIGNALING+0.460
- MYOGENESIS+0.410
- UV_RESPONSE_DN+0.410
- APICAL_JUNCTION+0.400
- NOTCH_SIGNALING+0.380
- ANGIOGENESIS+0.360
- TGF_BETA_SIGNALING+0.250
- KRAS_SIGNALING_UP+0.230
Top 10 suppressed
- E2F_TARGETS-0.730
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.620
- INTERFERON_ALPHA_RESPONSE-0.600
- MTORC1_SIGNALING-0.550
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.510
- INTERFERON_GAMMA_RESPONSE-0.490
- DNA_REPAIR-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613732 | — | A | 0.941 |
| 2 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.936 |
| 3 | s0122297 | — | — | 0.936 |
| 4 | TCGA-BH-A0EA-01A-11R-A115-07 | — | A | 0.929 |
| 5 | BSR_15_0097_A4_S88 | — | A | 0.924 |
| 6 | 20050037.TNBC | — | C | 0.918 |
| 7 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.916 |
| 8 | SRR1313111 | — | A | 0.904 |
| 9 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.900 |
| 10 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.530 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |